For Immediate Release
Eagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride Readyto-dilute and Rapid Infusion Injection Products to SymBio Pharmaceuticals Limited- Begins Process to Maximize Value of Eagle’s Product Portfolio Worldwide –- $12.5 Million Upfront Payment Plus Future Potential Milestones and Royalty Payments -WOODCLIFF LAKE, N.J. / TOKYO, JAPAN -- September 20, 2017 -- Eagle Pharmaceuticals,Inc. (Nasdaq: EGRX) (“Eagle” or “the Company”) and SymBio Pharmaceuticals Limited(“SymBio”) (Tokyo Stock Exchange/JASDAQ 4582) today announced that the Company haslicensed to SymBio rights under Eagle’s intellectual property to develop, market and sell Eagle’s
bendamustine hydrochloride (“bendamustine HCl”) ready-to-dilute (“RTD”) and rapid infusion(“RI”) injection products in Japan.
SymBio will be responsible for securing regulatory approval of the RTD and RI injection
products using the licensed technology in Japan with a target for approval of a product in 2020.
SymBio currently markets TREAKISYM® in Japan, a lyophilized powder formulation ofbendamustine HCl indicated for chronic lymphocytic leukemia (“CLL”); relapsed or refractory
low-grade Hodgkin’s lymphoma (“NHL”); mantle cell lymphoma (“MCL”); and as a first linetreatment of low-grade NHL and MCL. According to SymBio, 12-month sales ended June 30,
2017 in Japan for TREAKISYM were $52 million, due to the approval of first line treatment for
NHL and MCL in December 2016. SymBio has estimated that sales of TREAKISYM areestimated to grow to $90 million in 2018.
A 50 ml RI or rapid infusion presentation of bendamustine hydrochloride injection is currentlymarketed in the U.S. by Teva Pharmaceutical Industries, Ltd. (“Teva”) as BENDEKA®
(bendamustine HCl) Injection. BENDEKA currently has a 97% market share of thebendamustine market, and Teva has forecasted the North American market for bendamustine tobe approximately $600 - $660 million in sales in 2017. BENDEKA’s low volume infusion andshort infusion time represents an important benefit to both patients and healthcare providers.
Pursuant to the terms of the license with SymBio, Eagle will receive a $12.5 million upfront
milestone payment, and may be entitled to additional milestone payments upon approval and theachievement of cumulative sales thresholds. The Company will also receive royalties on future
net sales of the licensed bendamustine products.

“This is an important example of the value of the Eagle portfolio to patients worldwide and afirst step in expanding outside the U.S. for our differentiated products. We look forward toSymBio’s future approval and successful commercialization of bendamustine HCI in Japan,”stated Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals.
Mr. Fuminori Yoshida, President and Chief Executive Officer of SymBio, stated, “In-licensing
Eagle’s ready-to-dilute and rapid infusion injection products will enable SymBio to extend theproduct life and continue to maximize the value of TREAKISYM over the product life whilebringing significant benefits to patients and healthcare providers in Japan.”
About Eagle Pharmaceuticals, Inc.
Eagle is a specialty pharmaceutical company focused on developing and commercializing
injectable products that address the shortcomings, as identified by physicians, pharmacists andother stakeholders, of existing commercially successful injectable products. Eagle’s strategy is toutilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on theCompany’s website at www.eagleus.com.
Forward-Looking Statements
This press release contains forward-looking information within the meaning of the Private Securities
Litigation Reform Act of 1995, as amended and other securities laws. Forward-looking statements arestatements that are not historical facts. Words such as “will,” “may,” “intends,” “anticipate(s),”“plan,” “enables,” “potentially,” “forecasted”, “entitles,” and similar expressions are intended toidentify forward-looking statements. These statements include, but are not limited to, statements
regarding future events, including, but not limited to: forecasted sales of $90 million in 2018; forecasted
sales of Bendeka in 2018; SymBio’s plans to secure regulatory approval of bendamustine HCl in a 500ml
ready to infuse and/or a 50 ml rapid infusion presentation; SymBio’s target to market the smaller volume
product in Japan in 2020; the success of Eagle’s commercial relationship with SymBio and thecompanies’ ability to successfully work together; payments due to Eagle under the license with SymBio,including milestone and royalty payments; and other factors that are discussed in Eagle’s Annual Reporton Form 10-K for the year December 2016, and its other filings with the U.S. Securities and Exchange
Commission. All of such statements are subject to certain risks and uncertainties, many of which aredifficult to predict and generally beyond Eagle’s control, that could cause actual results to differ
materially from those expressed in, or implied or projected by, the forward-looking information andstatements. Such risks include, but are not limited to: whether SymBio will be successful atcommercializing the licensed products; whether Eagle and SymBio will perform their respective
obligations under the license agreement; inaccurate sales forecasts and estimates; the ability of SymBio
to obtain regulatory approval for its bendamustine products; and other risks described in Eagle’s filings
with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance onthese forward-looking statements that speak only as of the date hereof, and we do not undertake anyobligation to revise and disseminate forward-looking statements to reflect events or circumstances after
the date hereof, or to reflect the occurrence of or non-occurrence of any events.

About TREAKISYM®
TREAKISYM® (non-proprietary name: bendamustine HCl), a cytocide anti-cancer drug, is now
widely used in more than 50 countries with indications for low-grade non-Hodgkin’s lymphoma,
mantle cell lymphoma, and chronic lymphocytic leukemia.

TREAKISYM® Intravenous Infusion 100 mg was approved in October, 2010 for manufacturingand marketing for the indication of relapsed/refractory low-grade B-cell non-Hodgkin's
lymphoma and mantle cell lymphoma in Japan.
TREAKISYM® was approved for the additional indication of chronic lymphocytic leukemia inJapan in August, 2016.
TREAKISYM® Intravenous Infusion 25 mg, a standard low-dose product, was approved for
manufacturing and marketing in Japan in September, 2016.
TREAKISYM® was approved for the additional indication of first-line treatment of low-grade
B-cell non-Hodgkin’s lymphoma and mantle cell lymphoma in Japan in December, 2016.
TREAKISYM® has been marketed in Japan through Eisai Co., Ltd. since December, 2010.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who
previously served concurrently as Corporate VP of Amgen Inc. and founding President ofAmgen Japan. In May, 2016 SymBio incorporated its wholly-owned subsidiary in the U.S.,
called SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr.
Fuminori Yoshida). SymBio’s underlying corporate mission is to “deliver hope to patients inneed” as it aspires to be a leading global specialty biopharmaceutical company dedicated toaddressing underserved medical needs with main therapeutic focus in oncology, hematology andpain management.
Contacts:
Investor Relations for Eagle Pharmaceuticals,Inc:
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)